期刊
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY
卷 57, 期 3, 页码 98-108出版社
JAPANESE SOC LYMPHORETICULAR TISSUE RESEARCH
DOI: 10.3960/jslrt.17018
关键词
NK/T-cell lymphoma; prognostic model; treatment; guidelines
类别
资金
- Japan Society for the Promotion of Science (JSPS KAKENHI) [26461418, 17K09924]
- Grants-in-Aid for Scientific Research [17K09924, 26461418] Funding Source: KAKEN
Extranodal NK/T-cell lymphoma, nasal type (ENKL), is a form of lymphoma characterized by preferential extranodal involvement, Epstein-Barr virus (EBV) association, and geographic diversity in incidence. ENKL tumor cells express P-glycoprotein, which is related to multidrug resistance (MDR). This MDR phenomenon is thought to be the major reason why ENKL is resistant to anthracycline-containing chemotherapies and has led researchers to explore novel therapeutic strategies. Since the early 2000s, next-generation therapies, including upfront radiotherapy, chemotherapy, or concurrent chemoradiotherapy using non-MDR-related drugs, have markedly changed the management of ENKL. However, a recent large retrospective study in Japan revealed several limitations of next-generation therapies, in particular that they resulted in almost no improvement of early disease progression. This review will summarize the current management of ENKL, primarily based on clinical trial results, and provide clues for better future management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据